201 related articles for article (PubMed ID: 24373236)
1. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus.
Mo XL; Yang Z; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():95-131. PubMed ID: 24373236
[TBL] [Abstract][Full Text] [Related]
2. Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus.
Mo XL; Wei HK; Peng J; Tao YX
Prog Mol Biol Transl Sci; 2013; 114():251-76. PubMed ID: 23317787
[TBL] [Abstract][Full Text] [Related]
3. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
6. GPR119 as a fat sensor.
Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
[TBL] [Abstract][Full Text] [Related]
7. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
8. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
9. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
10. Physiology and therapeutics of the free fatty acid receptor GPR40.
Huang H; Dai MH; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235
[TBL] [Abstract][Full Text] [Related]
11. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
[TBL] [Abstract][Full Text] [Related]
14. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
[TBL] [Abstract][Full Text] [Related]
15. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic application of GPR119 ligands in metabolic disorders.
Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
[TBL] [Abstract][Full Text] [Related]
17. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
[TBL] [Abstract][Full Text] [Related]
18. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
Dhayal S; Morgan NG
Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid binding receptors and their physiological role in type 2 diabetes.
Swaminath G
Arch Pharm (Weinheim); 2008 Dec; 341(12):753-61. PubMed ID: 19009545
[TBL] [Abstract][Full Text] [Related]
20. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]